Article PDF
Avoid common mistakes on your manuscript.
References
Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol 2007;138;563–79.
Kastritis E, Zagouri F, Symeonidis A, Roussou M, Sioni A, Pouli A, et al. Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma. Leukemia 2014;28;2075–9.
Heaney JLJ, Campbell JP, Iqbal G, Cairns D, Richter A, Child JA, et al. Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials. Leukemia 2018;32;1727–38.
Gregersen H, Vangsted AJ, Abildgaard N, Andersen NF, Pedersen RS, Frølund UC, et al. The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study. Cancer Med 2017;6;1807–16.
Schütt P, Brandhorst D, Stellberg W, Poser M, Ebeling P, Müller S, et al. Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. Leuk Lymphoma 2006;47;1570–82.
Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis 2009;49;1211–25.
Blimark C, Holmberg E, Mellqvist UH, Landgren O, Björkholm M, Hultcrantz M, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica 2015;100;107–13.
Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002—Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005;23;9219–26.
Holmström MO, Gimsing P, Abildgaard N, Andersen NF, Helleberg C, Clausen NAT, et al. Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: a study based on the nationwide Danish Myeloma Database. Am J Hematol 2015;90;E73–E4.
Teh BW, Harrison SJ, Worth LJ, Spelman T, Thursky KA, Slavin MA. Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy. Br J Haematol 2015;171;100–8.
Sørrig R, Klausen TW, Salomo M, Vangsted A, Gimsing P. Risk factors for blood stream infections in multiple myeloma: a population-based study of 1154 patients in Denmark. Eur J Haematol 2018;101;21–7.
Szabo AG, Iversen KF, Möller S, Plesner T. The clinical course of multiple myeloma in the era of novel agents: a retrospective, single-center, real-world study. Clin Hematol Int 2019;1;220–8.
MiBa, the Danish Microbiology Database. Available from: https://miba.ssi.dk/service/english.
HAIBA - Bakteriæmi. Available from: https://miba.ssi.dk/haiba/casedefinitioner/bakteriaemi.
Author information
Authors and Affiliations
Corresponding author
Additional information
Peer review under responsibility of the International Academy for Clinical Hematology
Rights and permissions
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
About this article
Cite this article
Szabo, A.G., Iversen, K.F., Rosenvinge, F.S. et al. The Incidence and Timing of Blood Cultures in Multiple Myeloma — Results from a Retrospective, Single Center, Real-World Study. Clin Hematol Int 2, 168–172 (2020). https://doi.org/10.2991/chi.k.200719.001
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2991/chi.k.200719.001